Indicators
Indicators
Value
Direction
MACD(12,26,9)
-1.711
Neutral
RSI(14)
49.915
Neutral
STOCH(KDJ)(9,3,3)
25.954
Sell
ATR(14)
9.151
Low Volatility
CCI(14)
-36.602
Neutral
Williams %R
59.743
Sell
TRIX(12,20)
0.518
Sell
StochRSI(14)
0.000
Oversold
Search
Celcuity Inc
CELCAdd to Watchlist
124.470USD
-0.210-0.17%
Close 05/13, 16:00（ET）Quotes delayed by 15 min
6.02BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Celcuity Inc
Currency: USD Updated: 2026-05-12Key Insights
Celcuity Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 76 out of 383 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 156.73.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Celcuity Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Celcuity Inc Highlights
StrengthsRisks
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -32.93, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 47.21M shares, increasing 3.25% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 222.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.65.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
156.727
Target Price
+19.58%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-12The current financial score of Celcuity Inc is 6.30, ranking 259 out of 383 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low.
Score
Financials
6.16
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.53
Operational Efficiency
4.00
Growth Potential
6.75
Shareholder Returns
7.03
Celcuity Inc's Company Valuation
Currency: USD Updated: 2026-05-12The current valuation score of Celcuity Inc is 6.87, ranking 198 out of 383 in the Biotechnology & Medical Research industry. Its current P/E ratio is -32.93, which is -91.82% below the recent high of -2.69 and -16.28% above the recent low of -38.29.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 76/383
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-12The current earnings forecast score of Celcuity Inc is 8.73, ranking 69 out of 383 in the Biotechnology & Medical Research industry. The average price target is 108.00, with a high of 134.00 and a low of 94.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
156.727
Target Price
+24.74%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Celcuity Inc
CELC
12
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
25
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-12The current price momentum score of Celcuity Inc is 7.48, ranking 87 out of 383 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 148.27 and the support level at 103.83, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
127.312
Sell
MA10
130.967
Sell
MA20
126.265
Sell
MA50
118.811
Buy
MA100
112.654
Buy
MA200
89.483
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-12The current institutional shareholding score of Celcuity Inc is 10.00, ranking 1 out of 383 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 97.67%, representing a quarter-over-quarter increase of 12.26%. The largest institutional shareholder is PRFDX, holding a total of 1.21M shares, representing 2.50% of shares outstanding, with 37146.27% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-12The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Celcuity Inc. The Biotechnology & Medical Research industry's average is 3.36. The company's beta value is 0.09. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.09
VaR
+6.14%
240-Day Maximum Drawdown
+27.68%
240-Day Volatility
+147.17%
Return
Best Daily Return
60 days
+15.38%
120 days
+15.38%
5 years
+167.18%
Worst Daily Return
60 days
-7.66%
120 days
-8.04%
5 years
-17.53%
Sharpe Ratio
60 days
+1.45
120 days
+1.41
5 years
+0.72
Risk Assessment
Maximum Drawdown
240 days
+27.68%
3 years
+61.99%
5 years
+76.32%
Return-to-Drawdown Ratio
240 days
+39.28
3 years
+5.19
5 years
+1.40
Skewness
240 days
+12.38
3 years
+16.65
5 years
+15.09
Volatility
Realised Volatility
240 days
+147.17%
5 years
+96.20%
Standardised True Range
240 days
+3.72%
5 years
+1.27%
Downside Risk-Adjusted Return
120 days
+241.42%
240 days
+241.42%
Maximum Daily Upside Volatility
60 days
+50.73%
Maximum Daily Downside Volatility
60 days
+45.42%
Liquidity
Average Turnover Rate
60 days
+2.10%
120 days
+2.16%
5 years
--
Turnover Deviation
20 days
+65.10%
60 days
+25.60%
120 days
+28.70%
Peer Comparison
Biotechnology & Medical Research
Celcuity Inc
CELC
6.85 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
